Onco Actu du 5 janvier 2017

	1. Biologie
Comprehensive study of esophageal cancer reveals several molecular subtypes, provides new insight into increasingly prevalent disease [Dana-Farber] Results from this new report argue against the need to continue to debate the demarcations of esophageal and gastric adenocarcinoma and instead view gastroesophageal adenocarcinoma as a more singular entity, analogous to colorectal cancer.
	3.1 Tabac
Doctors urge Theresa May to publish anti-smoking strategy [The Guardian] In a letter to Theresa May, the senior doctors say the plan is essential to drive down smoking rates, which are highest and most damaging to health among the least well-off. The plan was due to be published last summer.
	4.9 Dép., diag. & prono. - Sein
Biomarker tests in breast cancer: Decision on chemotherapy remains difficult [ecancer news] At the moment one cannot in good faith advise a woman with a high clinical risk and low genomic risk to omit chemotherapy.
	5. Traitements
Little survival benefit and higher costs in advanced non-small cell lung cancer associated with new drugs [Colorado Cancer Blogs] What we see here doesn’t definitively mean these drugs are unsuccessful. It means that despite their promise in clinical trials, they haven’t made a survival difference in the population.
For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint Pain [NCI] The clinical trial showed that duloxetine (Cymbalta®), which is approved to treat depression and anxiety as well as fibromyalgia and nerve pain caused by diabetes, provided some relief from pain associated with aromatase inhibitors.
	5.12 Immunothérapies
Cancers Evade Immunotherapy By 'Discarding the Evidence' of Tumor-Specific Mutations [Johns Hopkins] Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.
Neon Therapeutics Hauls in $70M for Personalized Cancer Vaccines [Xconomy] Neon is currently testing its lead cancer vaccine, NEO-PV-01, in a Phase 1 clinical trial in combination with the Bristol-Myers Squibb drug nivolumab (Opdivo), which has already been approved to treat certain types of lymphoma and cancers of the skin, liver, lung, and head and neck.
	5.12.1 Immunothérapies - partenariats
MD Anderson and Affimed announce clinical immuno-oncology development collaboration [MD Anderson] This collaboration will leverage MD Anderson’s expertise in NK-cells and translational medicine and Affimed’s capabilities to develop tumor-targeting bispecific TandAb immune cell engagers.
	5.12.4 Immunothérapies - Essais
Lycera's double-action immuno-oncology drug starts trials [FierceBiotech] That process of reprogramming immune cells is "unique" and separates the company's candidates from other cancer immunotherapies that either stimulate the immune system or reduce immune suppression, he suggests.
	5.2 Pharma
Infinity Pharma R&D Chief Adams Retires Amid Restructuring, Job Cuts [Xconomy] Adams has worked at Infinity since 2003 and will step down this week amid a sweeping restructuring at the company, which closed down its research operations after an experimental cancer drug, duvelisib, came up short in clinical testing last year.
Former Novartis pharmaceuticals chief David Epstein is going biotech [EndPoints] Big pharma execs like Chris Viehbacher, ex-Sanofi CEO, and former AstraZeneca R&D chief Briggs Morrison also made the leap to biotech, which has been booming as the pharma giants struggle to maintain portfolios and fight off generic competition.
	5.3 Traitements - FDA, EMA, NICE...
You Wouldn’t Be Lying About That, Would You? [In the Pipeline] It’s easier for a company to blame Evil Regulatory Obstruction, but a big problem with that strategy is that people get a distorted view of the world.
	5.3.4 Traitements - AMM (FDA, EMA)
New FDA Drug Approvals: Breaking Down the Numbers [RAPS] And for those still claiming that FDA does not approve drugs faster than other countries: 19 of the 22 novel drugs approved in 2016 (86%) were approved in the US before any other country, which is similar to what occurred in 2015, when 29 of 45 approvals (64%) occurred first in the US.
A Review of CDER’s Novel Drug Approvals for 2016 [FDA Voice] The total number of novel drugs approved in 2016 is lower than the 45 novel drugs approved the year before and below the average of 29 drug approvals per year on average over the last 10 years. There are several reasons for this.
	6. Lutte contre les cancers
Combining health records and genome sequencing for precision medicine [PHG Foundation] By sequencing the exome (the part of the genome that codes for proteins) of 50,762 participants, and using patients’ de-identified electronic health records (EHRs) provided by Geisinger to match clinically documented phenotype data with sequencing data, researchers found over four million single nucleotide variants, insertions and deletions.
	6.10.1 Politiques (USA)
Biden to tackle broad range of cancer issues, including drug prices, after leaving White House [Washington Post] Now, Biden said, he is getting strong encouragement from throughout the cancer community to grapple with the pricing issue. “The researchers, the insurers, all of the major cancer centers . . . want me to pursue it.”
	6.4 Médico-éco
As health care costs spiral higher, hospital price increases are flying under the radar [HealthNewsReview] Prescription drugs, after all, eat up only about 10 percent of the spending pie. Hospitals consume about one-third, and doctors about one-fifth. Where’s the outrage when hospitals and doctors raise their prices? There isn’t much.